Viewing nowWinrica Capsule 150 mg (Pregabalin)
Pregabalin 150mg
Hard capsule · Prescription medication
Hanwha Pharmaceutical Co., Ltd.

MFDS item code 201800767 · Approved 2018.02.09 · Insurance code 651602330
Treatment of neuropathic pain and fibromyalgia, and adjunctive treatment of partial seizures in epilepsy
This medication is used for the treatment of peripheral and central neuropathic pain in adults. It is also utilized as an adjunctive therapy for partial seizures in people with epilepsy, regardless of the presence of secondary generalized symptoms. Additionally, it is effective in treating fibromyalgia. It provides extensive assistance for these various symptoms, improving the quality of life for patients.
This medicine is administered orally as pregabalin in two divided doses per day, regardless of food. It is excreted primarily by the kidneys, so the dose should be adjusted in patients with impaired renal function. (Refer to “5. Patients with Renal Impairment”) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: The recommended starting dose is 150 mg per day. Based on the individual patient’s response and tolerability, the dose may be increased to 300 mg per day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. 2) Central neuropathic pain Adults: The recommended starting dose is 150 mg per day. Based on the individual patient’s response and tolerability, the dose may be increased to 300 mg per day after 1 week. After an additional week, it may be increased to the target dose of 600 mg per day. If the target daily dose is not tolerated, dose reduction may be considered. (Refer to “4. Discontinuation”) 2. Epilepsy Adults: The recommended starting dose is 150 mg per day. Based on the individual patient’s response and tolerability, the dose may be increased to 300 mg per day after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg to 450 mg per day. The starting dose is 75 mg twice daily (150 mg per day), and may be increased to 150 mg twice daily (300 mg per day) within 1 week based on efficacy and tolerability. For patients who do not experience sufficient benefit at a dose of 300 mg per day, the dose may be increased to 225 mg twice daily (450 mg per day) within 1 week. Clinical studies have also been conducted at a dose of 600 mg per day, but there is no evidence of additional benefit or adequate tolerability at this dose. Given the dose-dependent adverse reactions, doses exceeding 450 mg per day are not recommended. 4. Discontinuation Based on current clinical experience, if treatment with this medicine is discontinued, it should be withdrawn gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this medicine is excreted primarily by the kidneys as unchanged drug. Because its clearance is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is calculated using the formula below. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose adjusted for renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) ≥60: Starting dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID ≥30 -<60: Starting dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID ≥15 -<30: Starting dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID <15: Starting dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: 25, 100, single dose b TID = Total daily dose administered in 3 divided doses BID = Total daily dose administered in 2 divided doses QD = Administered once daily a: The total daily dose (mg/day) should be divided as specified under the method of administration. b: A supplemental dose refers to an additional dose administered once. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Elderly patients (65 years and older) Dose reduction may be necessary in elderly patients with impaired renal function.
7. Pediatric and adolescent patients Use is not recommended in children under 12 years of age or adolescent patients aged 12 to 17 years because there are insufficient data on safety and efficacy.
This medication may increase the risk of suicidal thoughts or behaviors, so if any changes in mood or unusual behaviors occur during treatment, a doctor should be consulted immediately. This medication should not be administered to patients with hypersensitivity to it. Patients with diabetes may have difficulty controlling blood sugar due to weight gain, which may require dosage adjustments of their diabetes medications. If symptoms of angioedema, such as swelling of the face or around the mouth, occur, the medication should be stopped immediately, and medical advice sought. Elderly patients may experience increased dizziness or drowsiness, posing a risk of falls, so caution is required, and symptoms such as loss of consciousness or confusion can manifest. Blurred vision or changes in vision may occur; if these symptoms arise, inform healthcare personnel. Discontinuation of the medication may produce withdrawal symptoms such as insomnia, headache, nausea, or anxiety; therefore, do not stop abruptly without consulting a doctor. Due to the potential for drug misuse, patients with a history of substance abuse should be particularly cautious, and monitoring for signs of misuse or dependence is necessary. Patients with reduced kidney function may require dosage adjustments, and there have been reports of medication cessation effects upon improvement of kidney function. Patients with severe cardiac conditions should use this medication with caution. When taken with other medications that have central nervous system depressant effects, particularly opioids, the risk of respiratory depression increases; caution is warranted. In early pregnancy, there is a risk of congenital malformations in the fetus, so it is advisable not to take this medication during pregnancy, and women of childbearing age should use effective contraception. During breastfeeding, this medication could be passed to infants through breast milk, so consideration should be given to discontinuing breastfeeding or the medication. This medication may cause dizziness and drowsiness, necessitating precautions when driving or operating heavy machinery. Severe skin reactions may rarely occur; if abnormal symptoms such as skin rashes or swelling appear, cessation of the drug should be immediate, and a doctor should be consulted. In the case of overdose, symptoms such as confusion, drowsiness, or depression may appear, and blood dialysis may be required if necessary. Children, elderly patients, or those with reduced kidney function require particular caution and dosage adjustments when taking this medication. This medication is mostly excreted through urine, so the possibility of drug interactions with other medications is low; however, if taken with central nervous system depressants, effects may be enhanced.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent air or moisture entry, and kept in a cool place between 15 to 30 degrees Celsius. This storage method will help maintain the drug's effectiveness and prevent deterioration.
A white powder in a white hard capsule
30 capsules/bottle, 100 capsules/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowPregabalin 150mg
Hard capsule · Prescription medication
Hanwha Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.